Cagrilintide and Semaglutide + Placebo for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Feb 2024: Trial started, NCT06267092
  2. 20 Feb 2024: Trial registered, NCT06267092

The trials

NCT06267092: A Study of How CagriSema Works on Appetite in People With Excess Body Weight

State
Completed
Phase
Phase 1
People
164 taking part
Started
15 Feb 2024
Primary completion
7 Apr 2025
Arms
Part B
Results
None posted
  1. 15 Feb 2024: Trial started
  2. 20 Feb 2024: Trial registered
  3. 8 Dec 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.